Non-Hodgkin Lymphoma | Topics

 
Examining Social Inequity and Racial Disparities in T-Cell Lymphoma
October 14, 2021

As treatment for T-cell non-Hodgkin lymphomas continues to expand, disparities and inequities continue to grow for those within certain racial groups and of a certain socioeconomic status.

Emergency Fertility Preservation in a Young Woman With Non-Hodgkin Lymphoma
June 19, 2021

A nulliparous woman, age 25 years, had received a diagnosis of non-Hodgkin lymphoma and now presented with stage IIA diffuse large B-cell lymphoma. Due to potential risks of chemotherapy-induced gonadotoxicity and subsequent iatrogenic premature ovarian failure and fertility loss, the patient was referred to the reproductive medicine department for fertility preservation counseling and further management.

Regardless of Prior Anti-CD20 Therapy, Axi-Cel induces Durable Antitumor Activity in FL and MZL
June 15, 2021

CAR T-cell therapy with axicabtagene ciloleucel (axi-cel; Yescarta) showed promise in patients with high-risk relapsed/refractory indolent non-Hodgkin lymphoma.

CAR T-Cell Therapy, C-CAR066, Showed Promising Efficacy in R/R B-NHL
June 08, 2021

CAR066, showed a favorable safety profile and promising efficacy in the treatment of adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma who failed prior CD19 CAR T-cell therapy.

Odronextamab Shows Promise in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
December 06, 2020

A novel CD20xCD3 bispecific antibody, odronextamab, continues to show intriguing antitumor activity and an acceptable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, including those who have previously received chimeric antigen receptor T-cell therapy.

Combined HDAC, mTOR Inhibition Shows Clinical Efficacy in Relapsed/Refractory Hodgkin Lymphoma
October 15, 2020

This phase 1 study found that vorinostat (Zolinza) in combination with either sirolimus (Rapamune) or everolimus (Afinitor) demonstrated clinical efficacy in patients with relapsed and/or refractory Hodgkin lymphoma and warrants further investigation.

Study Identifies Characteristics of CAR T-Cell Products Associated with Outcomes in LBCL
October 07, 2020

Researchers identified molecular and cellular characteristics of anti-CD19 CAR T-cell infusion products associated with how patients with large B-cell lymphoma respond to treatment and experience adverse events.

Using HDAC3 Inhibitors to Reverse CREBBP Mutations in Lymphomas
January 13, 2020

This research could potentially pave the way for possible immunotherapy approaches for common forms of non-Hodgkin lymphoma.

CAR T-Cell Therapy Studies to Look for at the ASH Annual Meeting
November 27, 2019

Research on chimeric antigen receptor T-cell therapy to be presented at the ASH Annual Meeting & Exposition is set to address drawbacks associated with treatment.

Recent Research on Diabetes Mellitus, Non-Hodgkin Lymphoma Link
October 18, 2019

After conflicting opinions over the years, a study published in the journal Hematology explores the association between diabetes mellitus non-hodgkin lymphoma.